menu
    • menu
    [{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Cellectar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Agreement","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evergreen Theragnostics \/ Cellectar","highestDevelopmentStatusID":"8","companyTruncated":"Evergreen Theragnostics \/ Cellectar"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Clovis Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Agreement","leadProduct":"225-Ac FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Undisclosed","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evergreen Theragnostics \/ Evergreen Theragnostics","highestDevelopmentStatusID":"1","companyTruncated":"Evergreen Theragnostics \/ Evergreen Theragnostics"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Precirix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Partnership","leadProduct":"131-I Conjugated Anti-HER2 sdAb 2Rs15d","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evergreen Theragnostics \/ Precirix","highestDevelopmentStatusID":"7","companyTruncated":"Evergreen Theragnostics \/ Precirix"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Lantheus Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Acquisition","leadProduct":"177-Lu EVG-321","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Evergreen Theragnostics","amount2":1,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"Evergreen Theragnostics \/ Lantheus Holding","highestDevelopmentStatusID":"4","companyTruncated":"Evergreen Theragnostics \/ Lantheus Holding"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Medical University of Innsbruck","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Collaboration","leadProduct":"177-Lu EVG-321","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evergreen Theragnostics \/ Medical University of Innsbruck","highestDevelopmentStatusID":"4","companyTruncated":"Evergreen Theragnostics \/ Medical University of Innsbruck"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Petrichor Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Financing","leadProduct":"177-Lu EVG-321","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Evergreen Theragnostics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Evergreen Theragnostics \/ Petrichor Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Evergreen Theragnostics \/ Petrichor Healthcare"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"68-Ga EVG321","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evergreen Theragnostics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Evergreen Theragnostics \/ Undisclosed"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Orbit Discovery","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evergreen Theragnostics \/ Evergreen Theragnostics","highestDevelopmentStatusID":"4","companyTruncated":"Evergreen Theragnostics \/ Evergreen Theragnostics"}]

    Find Clinical Drug Pipeline Developments & Deals by Evergreen Theragnostics

    Menu

    Evergreen Theragnostics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Evergreen Theragnostics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Evergreen Theragnostics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu EVG-321

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Lantheus Holding

                            Deal Size : $1,002.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lantheus to Acquire Evergreen Theragnostics

                            Details : Through the acquisition, Lantheus will leverage Evergreen radiolabelled product pipeline, which includes EVG-321 (177Lu-EVG-321), is being evaluated for small cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : $250.0 million

                            January 28, 2025

                            Lead Product(s) : 177-Lu EVG-321

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Lantheus Holding

                            Deal Size : $1,002.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Evergreen Theragnostics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Evergreen Theragnostics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Orbit Discovery

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orbit, Evergreen Expand Research for Targeted Therapeutics Development

                            Details : The expanded collaboration will leverage Orbit’s proprietary screening platform to identify and optimize peptide candidates, combined with Evergreen’s expertise in radiopharmaceutical development.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 03, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Orbit Discovery

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Evergreen Theragnostics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Evergreen Theragnostics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga EVG321

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evergreen Opens CCK2-VIEW Phase II Trial in EU for Lung Cancer

                            Details : 68Ga-EVG321 is being evaluating in the early-stage clinical trials studies for the treatment of patients with small cell lung cancer in the European Union.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 18, 2024

                            Lead Product(s) : 68-Ga EVG321

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Evergreen Theragnostics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Evergreen Theragnostics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu EVG-321

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Medical University of Innsbruck

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Evergreen Theragnostics Licenses EVG321 from Innsbruck for Radioligand Therapies

                            Details : The collaboration aims to advance the clinical development of EVG-321 (177Lu-EVG-321), which is being evaluated in the early-stage clinical trial studies for the treatment of small cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            May 21, 2024

                            Lead Product(s) : 177-Lu EVG-321

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Medical University of Innsbruck

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Evergreen Theragnostics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Evergreen Theragnostics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu EVG-321

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Petrichor Healthcare

                            Deal Size : $26.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Evergreen Theragnostics Completes $26M Capital Raise for Radiopharmaceutical Pipeline

                            Details : Evergreen's financing supports clinical trials for its theragnostic pair, 177Lu-EVG-321 and 68Ga-EVG-321, aimed at small cell lung cancer treatment.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            April 16, 2024

                            Lead Product(s) : 177-Lu EVG-321

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Petrichor Healthcare

                            Deal Size : $26.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Evergreen Theragnostics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Evergreen Theragnostics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225-Ac FAP-2286

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Clovis Oncology

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Acti...

                            Details : Under the terms of the agreement, Evergreen will develop 225Ac-FAP-2286 at its facility in Springeld, N.J. The facility was purpose-built to develop and manufacture a variety of therapeutic radiopharmaceuticals, including those based on alpha-emitting is...

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            March 16, 2022

                            Lead Product(s) : 225-Ac FAP-2286

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Clovis Oncology

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Evergreen Theragnostics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Evergreen Theragnostics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 131-I Iopofosine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Cellectar

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, Now Known as ...

                            Details : The agreement with Evergreen provides long term commercial supply of iopofosine I-131 and supply of clinical study material for Cellectar’s pivotal study in Waldenstrom’s macroglobulinemia (WM) as well as ongoing Phase 1 and Phase 2 clinical studies.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            August 16, 2021

                            Lead Product(s) : 131-I Iopofosine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Cellectar

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Evergreen Theragnostics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Evergreen Theragnostics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 131-I Conjugated Anti-HER2 sdAb 2Rs15d

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Precirix

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Precirix Partners with Evergreen to Expand North American Clinical Trial Supply

                            Details : Under the terms of the deal, Evergreen will provide US-based manufacturing for Precirix’s lead product candidate, CAM-H2. CAM-H2 is being evaluated in a Phase I/II clinical trial targeting HER2-positive metastatic breast and gastric cancer.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            April 28, 2021

                            Lead Product(s) : 131-I Conjugated Anti-HER2 sdAb 2Rs15d

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Precirix

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth